(Q37214309)

English

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

scientific article published on 10 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

11

object named as

J-Y Blay

0 references

object named as

R Maki

3

0 references

author name string

A L Cesne

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

I Judson

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

F Grosso

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

S Schuetze

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

M V Mehren

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

S P Chawla

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

G D Demetri

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A Nieto

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A Tanovic

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

10 September 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

109

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1717-1724

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2013.524

0 references

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

A review of trabectedin (ET-743): a unique mechanism of action.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

6 September 2017

Epidemiological aspects of soft tissue sarcomas (STS)--consequences for the design of clinical STS trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

28 September 2017

EORTC elderly task force position paper: approach to the older cancer patient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

26 June 2018

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3790176

3 September 2018

Managing elderly soft tissue sarcoma patients-should age drive treatment?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24022187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The parallel lives of angiogenesis and immunosuppression: cancer and other tales

1 reference

https://pubmed.ncbi.nlm.nih.gov/24022187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24022187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soft-tissue sarcoma: Initial characteristics and prognostic factors in patients with and without metastatic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24022187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/24022187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anthracycline-induced cardiotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24022187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2013.524

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37214309&oldid=1694791799"